Baseline neutrophil-to-lymphocyte ratio is associated with outcome of ipilimumab-treated metastatic melanoma patients

Five-Year Survival Rates for Treatment-Naive Patients With Advanced Melanoma Who Received Ipilimumab Plus Dacarbazine in a Phase III Trial

(2015) Michele Maio et al.   JOURNAL OF CLINICAL ONCOLOGY

Three-year follow-up of advanced melanoma patients who received ipilimumab plus fotemustine in the Italian Network for Tumor Biotherapy (NIBIT)-M1 phase II study

(2014) A. M. Di Giacomo et al.   ANNALS OF ONCOLOGY

Immunological and biological changes during ipilimumab treatment and their potential correlation with clinical response and survival in patients with advanced melanoma

(2014) Ester Simeone et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Clinical experience with ipilimumab 3 mg/kg: real-world efficacy and safety data from an expanded access programme cohort

(2014) Paolo A Ascierto et al.   Journal of Translational Medicine

Ipilimumab for advanced melanoma

(2014) Alfonso Berrocal et al.   MELANOMA RESEARCH

Four-year survival rates for patients with metastatic melanoma who received ipilimumab in phase II clinical trials

(2013) J. D. Wolchok et al.   ANNALS OF ONCOLOGY

Experience in daily practice with ipilimumab for the treatment of patients with metastatic melanoma: an early increase in lymphocyte and eosinophil counts is associated with improved survival

(2013) J. Delyon et al.   ANNALS OF ONCOLOGY

Long-term survival and immunological parameters in metastatic melanoma patients who responded to ipilimumab 10 mg/kg within an expanded access programme

(2013) Anna Maria Di Giacomo et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Association of CTLA-4 Polymorphisms with Improved Overall Survival in Melanoma Patients Treated with CTLA-4 Blockade: A Pilot Study

(2013) P. Queirolo et al.   CANCER INVESTIGATION

CTLA-4 and PD-1/PD-L1 Blockade: New Immunotherapeutic Modalities with Durable Clinical Benefit in Melanoma Patients

(2013) P. A. Ott et al.   CLINICAL CANCER RESEARCH

The systemic inflammation-based neutrophil–lymphocyte ratio: Experience in patients with cancer

(2013) Graeme J.K. Guthrie et al.   CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY

Single-Center Experience With Ipilimumab in an Expanded Access Program for Patients With Pretreated Advanced Melanoma

(2013) Sofie Wilgenhof et al.   JOURNAL OF IMMUNOTHERAPY

CTLA-4 Blockade with Ipilimumab: Long-term Follow-up of 177 Patients with Metastatic Melanoma

(2012) P. A. Prieto et al.   CLINICAL CANCER RESEARCH

Hallmarks of Cancer: The Next Generation

(2011) Douglas Hanahan et al.   CELL

A prospective phase II trial exploring the association between tumor microenvironment biomarkers and clinical activity of ipilimumab in advanced melanoma

(2011) Omid Hamid et al.   Journal of Translational Medicine

Single-institution experience with ipilimumab in advanced melanoma patients in the compassionate use setting

(2010) Geoffrey Y. Ku et al.   CANCER

Ipilimumab experience in heavily pretreated patients with melanoma in an expanded access program at the University Hospital of Siena (Italy)

(2010) Anna Maria Di Giacomo et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

(2010) F. Stephen Hodi et al.   NEW ENGLAND JOURNAL OF MEDICINE

Guidelines for the Evaluation of Immune Therapy Activity in Solid Tumors: Immune-Related Response Criteria

(2009) J. D. Wolchok et al.   CLINICAL CANCER RESEARCH

Influence of Cytotoxic T Lymphocyte-associated Antigen 4 (CTLA4) Common Polymorphisms on Outcome in Treatment of Melanoma Patients With CTLA-4 Blockade

(2009) Willemijn B. Breunis et al.   JOURNAL OF IMMUNOTHERAPY